CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

BioPharma Dive
Original article

AstraZeneca invests $2B in Summit, gaining ‘seat at the table’ for PD-1/VEGF drug push

PartnershipivonescimabPositive
AI Analysis

Summary

AstraZeneca invests $2B in Summit Therapeutics and agrees to test Summit's ivonescimab alongside multiple AstraZeneca drugs, though the investment does not include ownership rights.

Importance:7/10
Sentiment:
0.60
partnershipequity investmentPD-1/VEGFclinical collaboration
Related Companies

Read the original article

Published by BioPharma Dive on September 29, 2026 12:49 PM

Read Original